402 related articles for article (PubMed ID: 23933154)
1. Genetics and epigenetics of sporadic thyroid cancer.
Vu-Phan D; Koenig RJ
Mol Cell Endocrinol; 2014 Apr; 386(1-2):55-66. PubMed ID: 23933154
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany.
Eszlinger M; Böhme K; Ullmann M; Görke F; Siebolts U; Neumann A; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Ruschenburg I; Paschke R
Thyroid; 2017 Mar; 27(3):402-411. PubMed ID: 28071986
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.
Nikiforov YE
Endocr Pathol; 2004; 15(4):319-27. PubMed ID: 15681856
[TBL] [Abstract][Full Text] [Related]
4. [Genetic causes of the thyroid carcinomas].
Jindrichová S; Vlcek P; Bendlová B
Cas Lek Cesk; 2004; 143(10):664-8. PubMed ID: 15584614
[TBL] [Abstract][Full Text] [Related]
5. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
6. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
[TBL] [Abstract][Full Text] [Related]
7. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.
Yoo SK; Lee S; Kim SJ; Jee HG; Kim BA; Cho H; Song YS; Cho SW; Won JK; Shin JY; Park do J; Kim JI; Lee KE; Park YJ; Seo JS
PLoS Genet; 2016 Aug; 12(8):e1006239. PubMed ID: 27494611
[TBL] [Abstract][Full Text] [Related]
9. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.
Nikiforova MN; Nikiforov YE
Expert Rev Mol Diagn; 2008 Jan; 8(1):83-95. PubMed ID: 18088233
[TBL] [Abstract][Full Text] [Related]
11. Pathology and genetics of thyroid carcinoma.
DeLellis RA
J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411
[TBL] [Abstract][Full Text] [Related]
12. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
13. Signaling pathways in follicular cell-derived thyroid carcinomas (review).
Romitti M; Ceolin L; Siqueira DR; Ferreira CV; Wajner SM; Maia AL
Int J Oncol; 2013 Jan; 42(1):19-28. PubMed ID: 23128507
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
[TBL] [Abstract][Full Text] [Related]
15. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
16. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
[TBL] [Abstract][Full Text] [Related]
17. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.
Tavares C; Melo M; Cameselle-Teijeiro JM; Soares P; Sobrinho-Simões M
Eur J Endocrinol; 2016 Apr; 174(4):R117-26. PubMed ID: 26510840
[TBL] [Abstract][Full Text] [Related]
18. Pax-8-PPAR-γ fusion protein in thyroid carcinoma.
Raman P; Koenig RJ
Nat Rev Endocrinol; 2014 Oct; 10(10):616-23. PubMed ID: 25069464
[TBL] [Abstract][Full Text] [Related]
19. [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
Maciel RM; Kimura ET; Cerutti JM
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):691-700. PubMed ID: 16444351
[TBL] [Abstract][Full Text] [Related]
20. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
